Holen Sie sich die Stockscreener-App
26.07
1.80%
0.46
Schlusskurs vom Vortag:
$25.61
Offen:
$25.6
24-Stunden-Volumen:
365.29K
Relative Volume:
0.85
Marktkapitalisierung:
$1.20B
Einnahmen:
$722.68M
Nettoeinkommen (Verlust:
$134.71M
KGV:
9.764
EPS:
2.67
Netto-Cashflow:
$109.94M
1W Leistung:
+1.40%
1M Leistung:
+0.19%
6M Leistung:
+1.80%
1J Leistung:
-36.18%
1-Tages-Spanne:
$25.47
$26.52
1-Wochen-Bereich:
$25.16
$26.52
52-Wochen-Spanne:
$20.39
$41.13
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Vergleichen Sie AMPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
26.07 | 1.18B | 722.68M | 134.71M | 109.94M | 2.67 |
|
ZTS
Zoetis Inc
|
122.25 | 54.31B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.47 | 45.90B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.86B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.06 | 34.53B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
510.94 | 21.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-12 | Hochstufung | Needham | Hold → Buy |
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Amphastar reports FDA approval for teriparatide injection - MSN
Will FDA Approval of an In‑House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative? - Yahoo Finance
Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile (NASDAQ:AMPH) - Seeking Alpha
Is FDA‑Cleared U.S.‑Made Teriparatide Pen Altering The Investment Case For Amphastar Pharmaceuticals (AMPH)? - simplywall.st
Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $44,623.53 in Stock - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $62,881.92 in Stock - MarketBeat
Amphastar Pharmaceuticals Director Sells Over 4,000 Shares - TradingView — Track All Markets
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Up 4.8%Still a Buy? - MarketBeat
Amphastar stock rises after FDA approval of teriparatide injection - Investing.com
Amphastar announces FDA approval for teriparatide injection - marketscreener.com
Amphastar Announces FDA Approval for Teriparatide Injection - Weatherford Democrat
What analysts say about Amphastar Pharmaceuticals Inc 29A stockTechnical Pattern Recognition & Access Free Tools and Start Investing - earlytimes.in
Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Its Recent Share Price Slide - Sahm
Dir Petersen Files To Sell 4,163 Of Amphastar Pharmaceuticals Inc [AMPH] - TradingView — Track All Markets
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to "Hold" at Barclays - MarketBeat
Is Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025? - Sahm
Barclays Initiates Coverage of Amphastar Pharmaceuticals (AMPH) with Equal-Weight Recommendation - Nasdaq
Amphastar Pharmaceuticals Breaks Below 200-Day Moving AverageNotable for AMPH - Nasdaq
Amphastar Pharmaceuticals (NASDAQ:AMPH) Coverage Initiated by Analysts at Barclays - MarketBeat
Barclays Initiates Amphastar Pharmaceuticals at Equalweight With $30 Price Target - marketscreener.com
Marshall Wace LLP Sells 183,037 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Falls 5.2% in Past Week as One-year Earnings and Shareholder Returns Continue Downward Trend - 富途牛牛
American Century Companies Inc. Sells 74,832 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Is Amphastar Pharmaceuticals Stock Built to Withstand a Pullback? - Trefis
Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Quantbot Technologies LP - MarketBeat
Why (AMPH) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Would You Still Hold Amphastar Pharmaceuticals Stock If It Fell 30%? - Trefis
Capital Fund Management S.A. Takes $931,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead? - Yahoo Finance
How Amphastar Pharmaceuticals Inc. (29A) stock expands through international marketsOptions Play & Free Community Supported Trade Ideas - Newser
Will Amphastar Pharmaceuticals Inc. stock outperform Nasdaq indexJuly 2025 News Drivers & Free High Accuracy Swing Entry Alerts - Newser
Will Amphastar Pharmaceuticals Inc. (29A) stock recover faster than industry2025 Retail Activity & Daily Profit Focused Stock Screening - Newser
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of "Hold" from Analysts - MarketBeat
Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why - The Globe and Mail
AMPH: Shifting to proprietary and biosimilar drugs, with major launches and global expansion ahead - TradingView — Track All Markets
Will Amphastar Pharmaceuticals Inc. (29A) stock benefit from infrastructure bill2025 Price Targets & Capital Protection Trade Alerts - Newser
Trend Recap: How strong is Amphastar Pharmaceuticals Inc stock revenue growth - BỘ NỘI VỤ
Will Amphastar Pharmaceuticals Inc. (29A) stock deliver stable dividendsWeekly Trade Recap & Precise Buy Zone Identification - Newser
Is Amphastar Pharmaceuticals Inc. stock a good choice for value investorsTrade Analysis Report & Long-Term Safe Return Strategies - Newser
Is Amphastar Pharmaceuticals Inc. (29A) stock at risk of policy regulationQuarterly Performance Summary & High Yield Equity Trading Tips - Newser
Can Amphastar Pharmaceuticals Inc. (29A) stock double in coming years2025 Price Targets & Real-Time Price Movement Reports - Newser
Creative Planning Acquires 22,493 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Geode Capital Management LLC Buys 18,161 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals (AMPH) Jumps 6.5% After Q3 Beat and Conference Reveal—Has the Investment Case Shifted? - Yahoo Finance
A Look at Amphastar Pharmaceuticals (AMPH) Valuation Following Strong Quarterly Results and Pipeline Progress - Yahoo Finance
VP Zhou Files To Sell 20,000 Of Amphastar Pharmaceuticals Inc [AMPH] - TradingView
SG Americas Securities LLC Acquires Shares of 24,448 Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Will Amphastar’s (AMPH) Q3 Earnings Beat Amid Margin Pressure Shift Its Competitive Narrative? - Sahm
Does Amphastar’s New Product Approvals Signal a Turning Point for the Stock in 2025? - Sahm
Magnetar Financial LLC Invests $306,000 in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar (AMPH) Q3 2025 Earnings Call Transcript - The Globe and Mail
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):